Previous studies have suggested that PP2, a Src kinase Fyn inhibitor, is able to inhibit Fyn activity and alter Tau expression in individuals with Alzheimer’s disease (AD) (Chen et al., 2013; Li and Gotz, 2017). This evidence concerns the gene MAPT and Alzheimer disease.